Logo image
Sign in
Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy Reply
Journal article

Lack of pretreatment cost-effectiveness and side effects of omalizumab versus prednisone/montelukast on tolerability of immunotherapy Reply

Marc Massanari, Harold Nelson, Thomas B. Casale and William Busse
Journal of Allergy and Clinical Immunology, Vol.127(2), pp.548-549
2011
PMID: 21281877

Metrics

3 Record Views

Details